Core Viewpoint - Shenzhen Core Medical Technology Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange, marking it as the first innovative medical device company to be accepted under the newly reinstated fifth set of listing standards for the Sci-Tech Innovation Board [1] Group 1 - Core Medical has received investments from multiple seasoned professional institutional investors [1] - It is the second company to be recognized as having seasoned professional institutional investors after Zhuhai Tenomab Pharmaceutical Co., Ltd. [1]

Group 1 - The Shanghai Stock Exchange has accepted the IPO application of Shenzhen Core Medical Technology Co., Ltd., marking it as the first innovative medical device company to be successfully accepted under the new fifth listing standard of the Sci-Tech Innovation Board [1] - Core Medical has undergone multiple rounds of financing, attracting investments from notable shareholders including Hillhouse Capital, Zhengxin Valley Investment, Lianxin Capital, Junlian Capital, Cornerstone Capital, and P7 China [1]

Core Insights - Shenzhen Core Medical Technology Co., Ltd. has received acceptance for its IPO application on the Sci-Tech Innovation Board, marking it as the first innovative medical device company to be accepted under the fifth set of listing standards since their reactivation [1][2] - The company focuses on providing comprehensive, innovative, and high-quality artificial heart products, addressing significant clinical needs in acute and chronic heart failure [1] - Core Medical has achieved key milestones and is expected to have a market value of no less than 4 billion yuan, with its main products requiring approval from relevant national authorities [1] Company Overview - Core Medical is dedicated to the iterative upgrade of artificial heart products through original innovation and key core technology breakthroughs [1] - The company meets the listing criteria outlined in the "Listing Rules," specifically requiring at least one core product to have obtained approval for Phase II clinical trials [1] Industry Context - The acceptance of Core Medical's IPO application highlights the growing market space and potential for innovative medical device companies within the healthcare sector [1][2]

Core Points - Shenzhen Core Medical Technology Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange on November 6, marking it as the first innovative medical device company to be accepted under the new fifth set of listing standards for the Sci-Tech Innovation Board [1] - The prospectus indicates that Core Medical has received investments from multiple experienced professional institutional investors [1]

Core Points - Shenzhen Core Medical Technology Co., Ltd. has had its IPO application accepted by the Shanghai Stock Exchange on November 6, marking it as the first innovative medical device company to be accepted under the fifth set of listing standards for the Sci-Tech Innovation Board [1] - The prospectus indicates that Core Medical has received investments from multiple qualified institutional investors, making it the second company after Zhuhai Tenomab Pharmaceutical Co., Ltd. to be recognized as having qualified institutional investors in its Sci-Tech Innovation Board application [1]

Market Overview - The medical services sector increased by 0.55% on November 6, with Haoyuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Top Gainers in Medical Services - Haoyuan Pharmaceutical (688131) closed at 77.71, up 4.13% with a trading volume of 44,300 shares and a transaction value of 338 million [1] - Bidai Pharmaceutical (688073) closed at 72.50, up 2.39% with a trading volume of 6,822 shares [1] - Innovative Medical (002173) closed at 24.25, up 2.32% with a trading volume of 448,800 shares and a transaction value of 1.077 billion [1] Top Losers in Medical Services - Baicheng Pharmaceutical (301096) closed at 54.08, down 3.41% with a trading volume of 128,600 shares and a transaction value of 706 million [2] - Berry Genomics (000710) closed at 13.79, down 2.41% with a trading volume of 277,400 shares [2] - Nossger (301333) closed at 64.59, down 2.05% with a trading volume of 33,800 shares [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 472 million from institutional investors, while retail investors saw a net inflow of 280 million [2][3] - Notable net inflows from retail investors were observed in Innovative Medical and other companies, despite overall sector outflows [3] Individual Stock Capital Flow - Innovative Medical had a net outflow of 37.53 million from institutional investors, while retail investors contributed a net inflow of 47.58 million [3] - Haoyuan Pharmaceutical saw a net inflow of 12.35 million from institutional investors, with a slight net outflow from retail investors [3] - Bidai Pharmaceutical had a significant net inflow of 8.77 million from retail investors, despite a net outflow from institutional investors [3]

Group 1 - The core viewpoint of the news is that Innovation Medical has shown significant stock performance with a year-to-date increase of 203.77%, despite a recent decline of 3.36% over the last five trading days [1] - As of November 6, the stock price reached 24.18 CNY per share, with a total market capitalization of 10.67 billion CNY [1] - The company has been actively traded, appearing on the "龙虎榜" (Dragon and Tiger List) 19 times this year, with the latest appearance on October 20, where it recorded a net buy of 242 million CNY [1] Group 2 - Innovation Medical operates primarily in the medical services sector, with 99.73% of its revenue coming from medical services and only 0.27% from other sources [1] - As of September 30, the number of shareholders increased to 130,200, a rise of 58.75%, while the average circulating shares per person decreased by 37.01% to 3,196 shares [2] - For the period from January to September 2025, the company reported a revenue of 597 million CNY, a year-on-year decrease of 2.11%, while the net profit attributable to the parent company was 4.72 million CNY, reflecting a year-on-year increase of 116.97% [2]

Group 1 - The training session aimed to enhance the quality and efficiency of innovative medical device application submissions, aligning with the State Council's directive for high-quality development in the pharmaceutical industry [1][3] - Over 10,000 participants from regulatory bodies, production companies, research institutions, and medical organizations attended the training, indicating strong interest and engagement in the topic [1][3] - Experts from the National Medical Products Administration provided insights on key aspects of the innovative medical device review process, addressing common issues and emphasizing the importance of clinical evaluation [3] Group 2 - The training focused on practical guidance for applicants, helping them navigate the innovative review application process and improve their understanding of clinical trial design and objectives [3] - The event fostered a collaborative environment where participants discussed common challenges and solutions, reinforcing a shared vision for the development of innovative medical devices [3] - This initiative serves as a significant step towards implementing national reforms in pharmaceutical regulation and enhancing the research and compliance capabilities of the medical device industry [3]

Core Insights - Innovation Medical (002173) reported a closing price of 24.59 yuan on October 27, 2025, with a 5.0% increase and a trading volume of 848,100 shares, resulting in a total transaction value of 2.077 billion yuan [1] Financial Performance - The company’s main revenue for 2025 was 597 million yuan, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders was 4.7244 million yuan, an increase of 116.97% [4] - In Q3 2025, the company reported a single-quarter main revenue of 196 million yuan, down 3.16% year-on-year, and a net profit of 16.0857 million yuan, up 236.15% year-on-year [4] - The company’s debt ratio stands at 17.84%, with investment income of 29.5055 million yuan and financial expenses of 605,500 yuan [4] Market Activity - On October 27, 2025, the net inflow of main funds was 41.3622 million yuan, accounting for 1.99% of the total transaction value, while retail investors saw a net inflow of 51.8033 million yuan, representing 2.49% of the total [1] - Over the past five days, the company experienced fluctuations in fund flows, with notable net inflows and outflows from different investor categories [1][2] Comparative Analysis - The company’s total market capitalization is 10.851 billion yuan, significantly lower than the industry average of 20.485 billion yuan, ranking 13th out of 42 in the medical services sector [4] - Key financial ratios indicate that the company has a price-to-earnings ratio of 1722.62 and a price-to-book ratio of 6.09, both of which are higher than the industry averages [4]

Core Viewpoint - Innovation Medical (002173) has shown a significant increase in stock price and net inflow of main funds, indicating positive market sentiment despite a decline in revenue [1][2]. Financial Performance - As of October 24, 2025, the stock price closed at 23.42 yuan, up 4.93%, with a trading volume of 788,100 hands and a total transaction amount of 1.84 billion yuan [1]. - The company reported a main revenue of 597 million yuan for the third quarter of 2025, a year-on-year decrease of 2.11%, while the net profit attributable to shareholders was 4.72 million yuan, up 116.97% year-on-year [5]. - The third quarter's single-quarter main revenue was 196 million yuan, down 3.16% year-on-year, with a single-quarter net profit of 16.09 million yuan, up 236.15% year-on-year [5]. Fund Flow Analysis - On October 24, 2025, the main funds had a net inflow of 220 million yuan, accounting for 11.95% of the total transaction amount, while retail investors experienced a net outflow of 143 million yuan, representing 7.77% of the total [1][2]. - Over the past five days, the main funds fluctuated, with a notable net outflow of 156 million yuan on October 23, 2025, and a significant net inflow of 545 million yuan on October 20, 2025 [2]. Financing and Margin Trading - As of October 24, 2025, the financing balance was 301 million yuan, with a net purchase of 134 million yuan on that day, marking a cumulative net purchase of 182 million yuan over three consecutive days [3][5]. - The company had no short selling activity, indicating a lack of bearish sentiment in the market [3]. Industry Comparison - Innovation Medical's total market value is 10.335 billion yuan, significantly lower than the industry average of 20.148 billion yuan, ranking 14th out of 42 in the medical services sector [5]. - Key financial ratios show that the company has a price-to-earnings ratio of 1640.65 and a price-to-book ratio of 5.8, both of which are considerably higher than the industry averages [5].